Dr. Thera Mulvania, President of Expression Systems, an Advancion company, has dedicated her entire academic and professional career to developing a deep expertise in the field of cell culture applications. She received her bachelor’s degree in biological sciences and a Ph.D. in microbiology and immunology from the University of California, Davis. In 2002, Dr. Mulvania joined Expression Systems as Principle Scientist and later became co-owner and Chief Operating Officer until it was acquired by Advancion Corporation in November 2022.
Webinar : Scalable Protein, AAV & Vaccine Production with Insect Cell & Baculovirus Expression
Watch our Webinar
The Baculovirus Expression Vector System (BEVS) is experiencing a resurgence as a highly effective and versatile platform for producing recombinant proteins, AAVs, and vaccines. In this webinar, you will discover key strategies for harnessing the robust power of the BEVS manufacturing platform in structural biology and gene therapy applications to enable high-yield, cost-effective production. In addition, you will gain new insights into the scalability of the BEVS platform to streamline production from small-scale to large-scale manufacturing.
Key topics to be covered:
BEVS Platform Overview & Applications: From GPCR proteins to AAV and vaccine production
Recombinant Baculovirus & Protein Optimization: Strategies for efficient, high-yield production
Scalability & Manufacturing Insights: From small-scale research to large-scale bioproduction
Featured Speaker
